US9512236B2
(en)
|
2006-12-19 |
2016-12-06 |
Ablynx N.V. |
Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
AU2007336242B2
(en)
|
2006-12-19 |
2012-08-30 |
Ablynx N.V. |
Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
EP2102244A2
(en)
|
2006-12-19 |
2009-09-23 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
|
FR2923383B1
(en)
*
|
2007-11-08 |
2010-03-19 |
Oreal |
USE OF AN N-ACYLATED SARCOSINATE AS A MICROBIAL ANTI-ADHESION AGENT.
|
US20110053865A1
(en)
|
2007-11-27 |
2011-03-03 |
Ablynx N.V. |
Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
|
US20110091462A1
(en)
|
2008-03-05 |
2011-04-21 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making and uses thereof
|
US8557965B2
(en)
|
2008-04-07 |
2013-10-15 |
Ablynx N.V. |
Single variable domains against notch pathway members
|
RU2010151725A
(en)
|
2008-05-16 |
2012-06-27 |
Аблинкс Нв (Be) |
AMINO ACID SEQUENCES AIMED AGAINST CXCR4 AND OTHER GPCR, AND COMPOUNDS INCLUDING THEM
|
WO2009147248A2
(en)
|
2008-06-05 |
2009-12-10 |
Ablynx N.V. |
Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
|
EP2352764B1
(en)
|
2008-10-14 |
2018-03-28 |
Ablynx N.V. |
AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
|
AU2009324354B2
(en)
|
2008-12-10 |
2016-04-14 |
Ablynx Nv |
Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
NZ595461A
(en)
|
2009-04-10 |
2013-01-25 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
EP3828201A1
(en)
|
2009-04-30 |
2021-06-02 |
Ablynx N.V. |
Method for the production of domain antibodies
|
WO2010139808A2
(en)
|
2009-06-05 |
2010-12-09 |
Ablynx Nv |
IMPROVED AMINO ACID SEQUENCES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (hRSV) AND POLYPEPTIDES COMPRISING THE SAME FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS
|
ES2804450T3
(en)
|
2009-07-10 |
2021-02-08 |
Ablynx Nv |
Method for producing variable domains
|
EP2473528B1
(en)
|
2009-09-03 |
2014-12-03 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
US9644022B2
(en)
|
2009-11-30 |
2017-05-09 |
Ablynx N.V. |
Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
US8962807B2
(en)
|
2009-12-14 |
2015-02-24 |
Ablynx N.V. |
Single variable domain antibodies against OX40L, constructs and therapeutic use
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
EP3501499B1
(en)
|
2010-02-11 |
2022-09-07 |
Ablynx NV |
Methods and compositions for the preparation of aerosols
|
WO2011117423A1
(en)
|
2010-03-26 |
2011-09-29 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
NZ603570A
(en)
|
2010-05-20 |
2014-12-24 |
Ablynx Nv |
Biological materials related to her3
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
WO2012056000A1
(en)
|
2010-10-29 |
2012-05-03 |
Ablynx Nv |
Method for the production of immunoglobulin single variable domains
|
PL2635607T3
(en)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
BR112013011003B1
(en)
|
2010-11-08 |
2021-12-07 |
Novartis Ag |
POLYPEPTIDE AND ITS USES, TRANSGENIC HOST CELL OF MICROORGANISM, MONOVALENT, BIVALENT, MULTIVALENT, BIPARATOPIC OR MULTIPARATOPIC NANOBODY, AND PHARMACEUTICAL COMPOSITION
|
AU2012234284B2
(en)
|
2011-03-28 |
2015-10-08 |
Ablynx Nv |
Bispecific anti-CXCR7 immunoglobulin single variable domains
|
PT2691415T
(en)
|
2011-03-28 |
2018-10-19 |
Ablynx Nv |
Method for producing solid formulations comprising immunoglobulin single variable domains
|
UA117218C2
(en)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
|
US9534039B2
(en)
|
2011-05-09 |
2017-01-03 |
Ablynx N.V. |
Method for the production of immunoglobulin single variable domains
|
CA2835340A1
(en)
|
2011-05-27 |
2012-12-06 |
Ablynx Nv |
Inhibition of bone resorption with rankl binding peptides
|
CN104271598A
(en)
|
2011-06-23 |
2015-01-07 |
埃博灵克斯股份有限公司 |
Immunoglobulin single variable domains directed against IgE
|
WO2013041722A1
(en)
|
2011-09-23 |
2013-03-28 |
Ablynx Nv |
Prolonged inhibition of interleukin-6 mediated signaling
|
CA2854233C
(en)
|
2011-11-04 |
2020-05-12 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
WO2013166594A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
JP6603209B2
(en)
|
2013-05-10 |
2019-11-06 |
ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ |
Protein modification of living cells using sortase
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
RU2017115670A
(en)
|
2014-10-10 |
2018-11-15 |
Аблинкс Н.В. |
RSV INFECTION TREATMENT
|
PT3204095T
(en)
|
2014-10-10 |
2019-07-11 |
Ablynx Nv |
Inhalation device for use in aerosol therapy of respiratory diseases
|
AU2015366284B2
(en)
|
2014-12-19 |
2021-07-22 |
Ablynx N.V. |
Cysteine linked nanobody dimers
|
CN108473561B
(en)
|
2015-11-27 |
2022-12-16 |
埃博灵克斯股份有限公司 |
Polypeptide inhibiting CD40L
|
SE543153C2
(en)
|
2016-05-19 |
2020-10-13 |
Biocool Ab |
Aqueous hydrogen peroxide solution obtained from a dry composition comprising sodium percarbonate for skin treatment
|
JP6992057B2
(en)
|
2016-06-10 |
2022-01-13 |
クラリティ コスメティックス インコーポレイテッド |
Non-acne-forming hair and scalp care products and how to use them
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
WO2018050833A1
(en)
|
2016-09-15 |
2018-03-22 |
Ablynx Nv |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
EP3541846A1
(en)
|
2016-11-16 |
2019-09-25 |
Ablynx NV |
T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
EP3589725A1
(en)
|
2017-02-28 |
2020-01-08 |
Vib Vzw |
Means and methods for oral protein delivery
|
KR20200005635A
(en)
|
2017-05-11 |
2020-01-15 |
브이아이비 브이지더블유 |
Glycosylation of Variable Immunoglobulin Domains
|
US20200190216A1
(en)
|
2017-06-02 |
2020-06-18 |
Merck Patent Gmbh |
Mmp13 binding immunoglobulins
|
EP3630818A1
(en)
|
2017-06-02 |
2020-04-08 |
Ablynx NV |
Aggrecan binding immunoglobulins
|
EP3630817A1
(en)
|
2017-06-02 |
2020-04-08 |
Merck Patent GmbH |
Polypeptides binding adamts5, mmp13 and aggrecan
|
MX2019014400A
(en)
|
2017-06-02 |
2020-02-10 |
Merck Patent Gmbh |
Adamts binding immunoglobulins.
|
JP7241731B2
(en)
|
2017-07-19 |
2023-03-17 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
serum albumin binder
|
CA3076791A1
(en)
|
2017-10-31 |
2019-05-09 |
Vib Vzw |
Novel antigen-binding chimeric proteins and methods and uses thereof
|
US11999797B2
(en)
|
2018-02-06 |
2024-06-04 |
Ablynx N.V. |
Methods of treating initial episode of TTP with immunoglobulin single variable domains
|
WO2019166622A1
(en)
|
2018-03-01 |
2019-09-06 |
Vrije Universiteit Brussel |
Human pd-l1-binding immunoglobulins
|
BR112020018908A2
(en)
|
2018-03-23 |
2021-01-26 |
Université Libre de Bruxelles |
wnt signaling agonist molecules
|
WO2020185069A1
(en)
|
2019-03-08 |
2020-09-17 |
Linxis B.V. |
Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
|
WO2020239945A1
(en)
|
2019-05-28 |
2020-12-03 |
Vib Vzw |
Cancer treatment by targeting plexins in the immune compartment
|
EP3976067A1
(en)
|
2019-05-28 |
2022-04-06 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
WO2021213435A1
(en)
|
2020-04-22 |
2021-10-28 |
迈威(上海)生物科技股份有限公司 |
Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
|
WO2021229104A1
(en)
|
2020-05-15 |
2021-11-18 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
EP4214235A1
(en)
|
2020-09-16 |
2023-07-26 |
LinXis B.V. |
Internalizing binding molecules
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
WO2022063947A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
EP4256067A2
(en)
|
2020-12-04 |
2023-10-11 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
US20240130999A1
(en)
|
2021-02-17 |
2024-04-25 |
Vib Vzw |
Inhibition of SLC4A4 in the Treatment of Cancer
|
IL305301A
(en)
|
2021-02-19 |
2023-10-01 |
Us Health |
SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
|
WO2022242892A1
(en)
|
2021-05-17 |
2022-11-24 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
WO2023281120A1
(en)
|
2021-07-09 |
2023-01-12 |
Luxembourg Institute Of Health (Lih) |
Dimeric protein complexes and uses thereof
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024008274A1
(en)
|
2022-07-04 |
2024-01-11 |
Universiteit Antwerpen |
T regulatory cell modification
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|